Panel Detects Demyelinating Neuropathy Biomarkers: John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S.

John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S., explain how Mayo Clinic Laboratories' new test panel can distinguish among various potential causes of demyelinating neuropathies. Test results are important for managing these devastating autoimmune conditions.Show notesSpeaker 3: (00:32) Would you provide a little background on yourself, Dr. Mills? Speaker 3: (01:19) Dr. Dubey? Speaker 3: (02:07) Can you give a brief overview of our demyelinating test and recommended use? Speaker 3: (03:52) Can you discuss how this new test will assist in a patient's journey? Speaker 3: (05:46) Can you tell us some of the unique features of this test? Speaker 3: (08:09) Dr. Dubey, as a neurologist, how does this test set us apart in the market? Speaker 3: (11:05) Could you summarize the benefits of having both a demyelinating panel and an axonal panel? Speaker 3: (11:40) Why should a patient have an axonal or demyelinating test versus a sensory and motor test for peripheral neuropathy?